Periosteal Osteosarcoma

Periosteal osteosarcoma is a malignant bone-forming tumour arising from the deep layer of the periosteum, growing outward on the cortical surface, with a predominantly chondroblastic phenotype and intermediate (grade 2) histological grade. It is the middle child of the surface osteosarcoma family.

• Cell of origin: cambium layer of periosteum; the tumour therefore sits on, and erodes into, the outer cortex rather than arising within the medulla.
• Site: diaphysis or metadiaphysis of femur (approximately half) and tibia (approximately one third); humerus, ulna, ribs and jaw are described. Circumferential involvement is uncommon — the lesion typically occupies one aspect of the shaft.
• Age: peak in the second and third decades, essentially overlapping conventional osteosarcoma, and a decade younger than parosteal.
• Genetics: unlike parosteal osteosarcoma, periosteal lesions do not show consistent MDM2/CDK4 amplification. A negative MDM2 FISH therefore supports periosteal over parosteal when the imaging is ambiguous, but does not exclude conventional osteosarcoma.
• Behaviour: metastasises to lung in a minority; regional nodal spread is not a feature. Local behaviour is dominated by the soft-tissue component.

• Enneking (MSTS) surgical staging: periosteal osteosarcoma with an extraosseous soft-tissue mass and no metastasis is typically Stage IIB (high grade by Enneking's two-tier system, extracompartmental, M0). Enneking's binary grading forces intermediate lesions into the high-grade box — say this explicitly in a viva rather than pretending the system is finer than it is.
• AJCC: T-stage by size (8 cm threshold), G by grade, M by site of metastasis (lung versus other).
• MDT decisions to settle before theatre: grade confirmation on adequate tissue; true marrow status; osteotomy levels; reconstruction strategy; whether chemotherapy will be offered and, if so, whether neoadjuvantly (which allows assessment of necrosis) or adjuvantly.
• Fertility and growth: if chemotherapy is planned in an adolescent, arrange fertility counselling and gamete/ovarian tissue preservation before the first cycle. Consider remaining growth in the reconstruction plan for skeletally immature patients.

Principles

• Wide en-bloc resection is the treatment. Because the medulla is spared, most tumours are amenable to diaphyseal (intercalary) segmental resection preserving both adjacent joints — a major functional advantage over conventional osteosarcoma.
• The critical margins are the soft-tissue cuff over the mass (take an uninvolved layer of muscle or fascia across the entire surface, never dissect on tumour) and the bone cuts (2 to 3 cm of normal marrow beyond MRI-defined extent, confirmed with intraoperative frozen section of marrow from each cut end).
• If a portion of cortex is uninvolved circumferentially and the tumour is truly limited to one aspect, a hemicortical resection with hemicortical allograft is described and preserves continuity — but only where MRI proves circumferential sparing and margins are achievable. Most surgeons reserve this for parosteal lesions and are more conservative with periosteal disease.
• Amputation is reserved for tumours encasing the neurovascular bundle beyond reconstruction, extensive contamination from unplanned surgery, or fungation/infection.

PIPADRAW — Intercalary femoral diaphyseal resection with intercalary reconstruction

A defensible position for a viva: "There is no randomised evidence that chemotherapy improves survival in periosteal osteosarcoma, and retrospective series have not shown a consistent benefit. Surgery with a wide margin is the mainstay. Many centres nonetheless offer conventional osteosarcoma chemotherapy to young patients, particularly where the tumour is large, the grade is heterogeneous, or the margin is compromised. I would take the case to the sarcoma multidisciplinary meeting and consent the patient with an honest account of the uncertainty."

Radiotherapy has no established role in primary management; it is reserved for unresectable disease, positive margins where re-excision is impossible, or palliation.

Prognosis

• Long-term survival 85 to 90% with a wide, negative margin — intermediate between parosteal (greater than 90%) and high-grade surface or conventional osteosarcoma.
• Pulmonary metastases in 10 to 15%, typically within the first 3 years but late events occur.
• Adverse factors: inadequate margin, local recurrence, large tumour volume, high-grade foci, true medullary invasion, metastasis at presentation.
• Resectable pulmonary metastases should be considered for metastasectomy — prolonged survival after complete resection of limited lung disease is well documented across osteosarcoma generally.

Surveillance schedule

Complications of treatment

Global epidemiology. Osteosarcoma incidence is broadly similar worldwide (roughly 3 to 4 per million per year across all subtypes), with periosteal osteosarcoma accounting for only 1 to 2%. Because absolute numbers are tiny, no single centre accumulates a large series and evidence is inevitably retrospective and multi-institutional. Outcome differences between regions are driven far more by time to referral and access to reconstruction than by tumour biology.

Society and network guidance (where it genuinely addresses this topic):

Registry and network evidence. There are no arthroplasty-style implant registries for this disease. The relevant datasets are national and supranational bone sarcoma registries and cooperative group databases (European Musculoskeletal Oncology Society registries, cooperative osteosarcoma study groups, national cancer registries), which pool rare variants to generate the survival and chemotherapy-response figures quoted above. Where segmental endoprostheses are used, national implant and tumour-prosthesis audits contribute long-term revision data.

Practice variation by resource setting.

• High-resource centres: MRI-planned intercalary resection, allograft banking, microvascular reconstruction, PET staging, fertility preservation, protocol chemotherapy where chosen.
• Intermediate-resource settings: intercalary resection with autograft, non-vascularised fibula, or bone transport where allograft banks and microsurgery are unavailable; CT chest available but PET is not.
• Low-resource settings: late presentation with large masses, limited pathology expertise (risk of misdiagnosis as a cartilage tumour), and higher amputation rates. The single highest-yield intervention in these settings is early referral and correct biopsy, not access to chemotherapy.

1. Does chemotherapy help? The central unresolved question. No randomised data; retrospective series conflict and are underpowered. Practice ranges from surgery alone in all cases to routine conventional protocols in all young patients.
2. What counts as medullary invasion? MRI reactive oedema is over-called. Some argue any T1 marrow change reclassifies the tumour; others require confluent replacement plus histological confirmation. The threshold materially changes both grade assignment and chemotherapy decisions.
3. Is periosteal osteosarcoma a distinct entity or a spectrum? Some pathologists regard it as one end of a continuum with high-grade surface osteosarcoma, with the grade determined by sampling. Inadequate biopsy sampling can misgrade either way.
4. Hemicortical versus segmental resection. Hemicortical excision preserves continuity and function but the oncological safety margin in an intermediate-grade tumour with periosteal spread is less secure than in parosteal disease. Most units resect segmentally.
5. Best intercalary reconstruction. Allograft, vascularised fibula, Capanna construct, intercalary endoprosthesis and bone transport all have advocates; comparative data are small-series and centre-dependent. Choice is driven by defect length, host biology, chemotherapy exposure and local microsurgical capability.
6. Duration of surveillance. Late metastasis and late reconstruction failure both occur; whether chest imaging should continue beyond 10 years is not settled.